Bigul

SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Resignation of Director

With reference to the captioned subject, we hereby wish to inform that the Board of Directors at their meeting held on 08 February 2022, inter alia discussed and took note the following; Resignation of Mr. Naresh Patwari as a Non-executive Director of the Company with effect from 02 February 2022. Resignation of Mr. Piyush Goenka as an Independent Director of the Company with effect from 07 February 2022. Request you to take the same on record.
09-02-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Update on Slump sale of Active Pharmaceutical Ingredient (API) business of the Company
09-02-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Board Meeting Outcome for OUTCOME OF BM - FINANCIAL RESULTS

Approval of Unaudited Standalone and Consolidated Financial Results of the Company for the Third Quarter ended 31 December 2021.
08-02-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Outcome Of Board Meeting. - Financial Results

Approval of Unaudited Standalone and Consolidated Financial Results of the Company for the Third Quarter ended 31 December 2021.
08-02-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Board Meeting Intimation for Intimation Of The Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2022 ,inter alia, to consider and approve Approval of the un-audited Standalone and Consolidated Financial Results of the Company for the Third Quarter ended 31 December, 2021.
02-02-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Announcement U/R 30 Of SEBI(LODR)

Shilpa's Pemetrexed Injection 1000 mg/100 ml, 500 mg/50 ml & 100 mg/10 ml, Ready to Use formulation is approved by European Authorities
21-01-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Statement Of Investor Complaints For The Quarter Ended December 2021

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- V V KRISHNA CHAITANYADesignation :- Company Secretary and Compliance Officer
18-01-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Closure of Trading Window

In line with the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 amended vide SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018 read with Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, it is hereby informed that the trading window of Shilpa Medicare Limited shall remain closed for dealing in securities of the Company for all Designated Employees/Persons and their immediate relatives with effect from 01 January 2022 till 48 hours after declaration of the financial results for the third quarter ending 31 December 2021
31-12-2021
Bigul

SHILPA MEDICARE LTD. - 530549 - Shilpa Medicare Limited Has Launched 'PRUCALSHIL (Prucalopride) Orally Disintegrating Strips 1 Mg And 2 Mg' In India

This is to inform you that the Company has launched PRUCALSHIL (Prucalopride) Orally Disintegrating Strips 1 mg and 2 mg' in India, a unique formulation developed for the first time in the World. The company has developed a novel 'Orally Disintegrating Strip (ODS)' formulation for Prucalopride and obtained subsequent approval from Drug Control General of India. Prucalopride is used for symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief.
21-12-2021
Bigul

SHILPA MEDICARE LTD. - 530549 - Intimation U/R 30.

Shilpa Medicare Limited, Unit III R&D facility clears US FDA Remote Record Review with no observations.
19-11-2021
Next Page
Close

Let's Open Free Demat Account